GLAND PHARMA
|
The Current P/E Ratio of GLAND PHARMA is 34.98.
| Share Price | ₹1,798.0 | Apr 22,2026 |
| Market Cap | ₹29,630.2 Cr | |
| Earnings-TTM | ₹847.2 Cr | TTM-Consolidated Results |
| Price/Earnings | 34.98x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of GLAND PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹29,630.2 Cr] as on Apr 22,2026
(/) Earnings [ ₹847.2 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 34.98x ]
Thus, for GLAND PHARMA , the investors are currently willing to pay 34.98 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLAND PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLAND PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of GLAND PHARMA
PE Ratio Performance Analysis for GLAND PHARMA
- GLAND PHARMA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 37.71x.
- GLAND PHARMA 's operated at median p/e ratio of 39.27x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLAND PHARMA 's p/e ratio peaked in Mar2022 at 44.33x.
- GLAND PHARMA 's p/e ratio hit its five-year low in Mar2023 of 26.75x.
How does GLAND PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| GLAND PHARMA | 847.18 | 34.98 | 29,630.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 36.40 | 400,497.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 67.34 | 166,939.0 |
| CIPLA LTD | 4,544.70 | 21.95 | 99,761.1 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 60.79 | 138,109.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 18.44 | 101,578.0 |
| MANKIND PHARMA LTD | 1,796.65 | 51.36 | 92,275.4 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.96 | 93,539.5 |
| LUPIN LTD | 4,669.18 | 22.59 | 105,496.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 23.49 | 82,526.1 |
| ABBOTT INDIA LTD | 1,524.13 | 35.43 | 54,003.9 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLAND PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.44x |
| Max industry PE | 67.34x |
| Median industry PE | 34.98x |
| Average industry PE | 35.61x |
You may also like the below Video Courses